<DOC>
	<DOC>NCT00309049</DOC>
	<brief_summary>The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.</brief_summary>
	<brief_title>Ixabepilone Administered as an Enteric Coated Formulation.</brief_title>
	<detailed_description />
	<mesh_term>Epothilones</mesh_term>
	<criteria>ECOG status of 02. Unable to swallow pills. Current or recent GI disease or GI surgery. Brain mets. Severe nerve damage. ANC &lt;1,500/mm3 Platelets &lt;125K. Bilirubin &gt;=1.5 times the IULN. ALT/AST &gt;=1.5 times the IULN. Creatine &gt;1.5 times the IULN. Prior treatment with Ixabepilone. Strong use of CYPP450 drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>